Here are two such growth stocks that Wall Street rates as a “Strong Buy” and believes will generate more than 300% returns ...

So should Vaxcyte (NASDAQ:PCVX) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn ...

We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential. In this ...

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

Novavax (NASDAQ: NASDAQ:NVAX) stock plummeted 24% after comments from Health and Human Services Secretary Robert F. Kennedy Jr. suggested a shift in government priorities away from the company’s ...

Politically Georgia brings you insights and analysis from Peachtree Street to Pennsylvania Avenue. Sign up for our exclusive ...

Highlights,Institutional holdings in Vaxcyte have expanded, with major firms adjusting their positions.,Janus Henderson Group and Capital Research Global Investors reported notable stake ...

Vaxcyte (NASDAQ:PCVX – Free Report) had its price target cut by The Goldman Sachs Group from $138.00 to $100.00 in a report released on Tuesday,Benzinga reports. They currently have a buy rating on ...

Vaxcyte, Inc.'s stock plummeted nearly 50% despite positive Phase 2 results for its VAX-24 pediatric vaccine amid concerns over government vaccine skepticism and competitive threats. The new ...

The last time I spoke about Vaxcyte, Inc. (NASDAQ:PCVX) it was in a Seeking Alpha article entitled "Vaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball Rolling." With respect to this ...